BACE1 activity is normally found to increase in AD conditions, however, pretreatment with the selected compounds (10, 12, 16, and 18) showed an effective decrease of BACE1 activity in the Aβ42-induced cells (Fig. 5). Here, BACE1 is linked to Alzheimer disease.